The identification of predictive genetic markers in PTGS2, IL4 and PIK3CA highlights, for the first time, the relevance of tumour microenvironment, inflammatory response and PI3K/AKT pathway activation in sunitinib treatment resistance. The gene discussed is IL4; the disease is neoplasm.